Different aspects of opioid use in rheumatoid arthritis patients

Dorota Sokól¹, Adrian Undziakiewicz¹, Iga Dudek¹, Jakub Czarnota¹, Małgorzata Drozd¹, Michał Dobrzyński¹, Tomasz Skubel¹, Halina Pieciewicz-Szcześnią²

¹Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
²Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin

Corresponding author: Dorota Sokól, e-mail: dorota.sokol9606@gmail.com

ORCID ID:
Dorota Sokól: https://orcid.org/0000-0003-2059-7951; dorota.sokol9606@gmail.com
Adrian Undziakiewicz: https://orcid.org/0000-0002-1191-1366; adrian.undziakiewicz@gmail.com
Jakub Czarnota: https://orcid.org/0000-0003-2783-0349; kubbbaa232@interia.pl
Michał Dobrzyński: https://orcid.org/0000-0002-1416-6568; mdobrzyski4@gmail.com
Małgorzata Drozd: https://orcid.org/0000-0002-0710-2451; drozd.malg@gmail.com
Iga Dudek: https://orcid.org/0000-0002-8101-074X; iga.dudek6@gmail.com
Tomasz Skubel: https://orcid.org/0000-0001-7572-401X; tomasz.wojciech.skubel@gmail.com
Halina Pieciewicz-Szcześnią https://orcid.org/0000-0002-0573-7226; halpiec@wp.pl

Abstract

Background: Rheumatoid arthritis (RA), chronic severe non-cancer pain and the use of prescription opioids are now an increasing and common problem. Both RA and its comorbid pain have different mechanisms and their control can prove challenging, especially when patients are unresponsive to non-opioid analgesics or have side effects.

The aim of the study is to analyze the available results of research and meta-analyzes on the use of opioids among patients with rheumatoid arthritis.

Materials and methods: the literature available on the PubMed platform and published between 2010 and 2020 was analyzed.

Results and conclusions: The use of opioids can cause a number of side effects, including misuse, abuse or addiction to these drugs. These phenomena are becoming more common in European and North American populations, as well as more and more people are using...
opioids in long-term therapy, despite the lack of evidence of a positive effect of such treatment in people with RA. In RA patients, frequent combinations of opioids with other drugs, for example benzodiazepines or anti-anxiety agents, are also observed, as well as side effects specific for this group of patients, such as osteoporotic fractures.

**Key words:** opioids, rheumatoid arthritis, chronic pain

**Background**

Rheumatoid arthritis (RA) in the adult population has an estimated incidence of 0.5-1%, affects mainly women, and the mean age of onset is 35-50\(^1,2\). RA is a chronic autoimmune disease that can damage many joints and cause disability, but pain is the most common reason for seeing a doctor\(^3\). A study in Norway indicates that chronic pain associated with RA is also an area where 68.6% of patients expect improvement during treatment\(^4,5\), but its control is a challenge. First, more and more research show that pain severity may not necessarily correlate with disease activity\(^6,7\) because the components of inflammation are not the only factor causing pain\(^8,9\). Despite good disease control, joint pain may also persist in remission, which, as shown in animal models, is related to the multifactorial nature of pain in RA, having a source in inflammatory mechanisms that affect nociceptors, as well as neuropathic, central and central mechanisms\(^9\), but pain may also be associated with mental disorders, disability and poor mental adaptation to the disease\(^10\). The main group of analgesics prescribed to patients with RA are non-selective non-steroidal anti-inflammatory drugs (NSAIDs), which are useful in the first weeks after clinical onset of RA\(^11\), but gastrointestinal disorders (including gastric ulcer, dyspepsia, nausea and vomiting), liver and kidney disorders, asthma, allergic rash, hematopoiesis disorders are common side effects\(^12\). Selective COX-2 inhibitors are more and more often used in RA therapy, which have anti-inflammatory and analgesic effects similar to non-selective NSAIDs, but with fewer gastrointestinal complications\(^11,13\). However, it turns out that very often pain control with these drugs is insufficient. The increasing and chronic use of opioids in the treatment of chronic non-cancer pain in recent years has led to an "opioid epidemic" with increasing abuse and dependence on these drugs\(^14,15\).

**Characteristics of opioids**

The main function of opioids is analgesic action, which is an effect of drugs’ influence on \(\mu\), \(\kappa\) and \(\delta\) receptors, widely distributed in the central and peripheral nervous system\(^16\). In addition to this effect, there are also a number of side effects, ranging from the most common nausea and vomiting\(^17\), behavioral disorders, somnolence, impaired sleep regulation and insomnia, endocrine disorders, sleep apnea, respiratory depression, abuse and addiction\(^18\). The latter, according to the U.S. Food and Drug Administration, are serious adverse events\(^19\). In addition, drug-drug interactions and alcohol-drug interactions, which may exacerbate or cause side effects, are important issues with chronic opioid use\(^18\). The most commonly used chronic
opioids in the US are oxycodone, tramadol, hydrocodone, fentanyl, codeine and morphine. In Poland, the most commonly used opioids in 2000 were morphine and fentanyl, while in 2015 the first place was taken by tramadol, mainly due to the widespread use of preparations combining both paracetamol and tramadol.

**Changes in opioids use**

Numerous studies indicate an increase in the use of opioids among RA patients, as well as an increasing chronic use of these drugs. In a cohort study conducted in the US in 2002-2015, the criterion of chronic opioid use was defined on the basis of documented opioid use during at least two follow-up visits, with the median time between two visits being 156 days. In the study group, the percentage of chronic opioid users more than doubled from 7.4 in 2002 to 16.9 in 2015. Another study found that patients with RA in 2014 were 1.5 times more likely to use opioids than those without RA (40% vs 24%) and were almost twice as likely to use opioids chronically (12% in RA vs 4% in non-RA patients, the rate index was adjusted for age and gender), with the study assuming that chronic opioid use was considered to be providing the patient with a prescription for 60 days or longer. Another cohort study completed in 2014 indicates that 41% of RA patients use opioids regularly (chronic use is defined as having at least 3 opioid prescriptions or taking them for at least 90 days), 40% use them sporadically, and 19% do not take them at all. All the above-mentioned studies also confirm the increase in the incidence of both incidental and chronic opioid use in the RA patients population in the United States in recent years, with the highest percentage in 2010 and a slight decrease by 2014. In addition, more frequent chronic opioid use was reported among women aged 50-67.

**Opioids and rheumatoid arthritis**

There are few studies on the effectiveness of opioids in the treatment of pain associated with RA, and evidence of their effectiveness is weak. Most studies refer to weak oral opioids and identify these drugs as beneficial in treating pain associated with RA, while paying attention to possible side effects, but the results of these studies are also burdened with a high risk of error. Another study indicates that opioid use for less than 1 month may have a positive effect on health-related quality of life (HRQoL) measured by a physical and mental component survey.

Although there are indications of the efficacy and relative safety of opioids, they only apply to short-term use. There are no clinically relevant data on the use of opioids in patients with RA for more than 8 weeks. There was also no evidence that the efficacy of analgesia could be sustained after eight weeks of continuous opioid use in any form of chronic non-cancer pain.

The cohort studies also highlighted the medications that RA patients used concomitantly with chronic opioids. In one of the studies slightly more than 40% of respondents took biological DMARDs, 27% took glucocorticosteroids and almost 18% took antidepressants. To this list other studies add the frequent use of benzodiazepines, antiepileptic drugs and the use of non-opioid analgesics such as acetaminophen or NSAIDs.
The observed relationship between the use of opioids and biological drugs and glucocorticosteroids may result from the fact that people who require biological treatment are characterized by greater disease activity and greater pain intensity\textsuperscript{21}. On the other hand, it seems that the low level of parameters and symptoms of inflammation does not equal reduced pain and fatigue\textsuperscript{6}. A study in Iceland found that 75\% of patients had used opioid analgesics in two years before and/or after starting treatment with a TNF inhibitor, with the proportion of patients taking opioids rising before starting treatment and then falling back to an earlier level\textsuperscript{29}, which may indicate the fact that better control of RA activity does not necessarily lead to a decline in opioid use\textsuperscript{14}.

A high proportion of patients who take antidepressants and opioids concurrently corresponds to the data indicating that depression occurs in 22.5\% of patients with chronic pain\textsuperscript{30}, while in RA patients depressive symptoms were observed in 12-55\% of respondents, depending on the kind of questionnaire used and its level of detail\textsuperscript{31}. Moreover, it was determined that in the group of patients with mainly moderate or high RA activity measured with DAS23, a depressive episode in the course of recurrent depression is an important factor in the persistence of pain, and tailored antidepressant treatment leads to a lasting reduction in pain intensity\textsuperscript{32}. On the other hand, chronic pain and inflammation increase the risk of depressive symptoms, but it is unclear whether chronic pain is a depressive factor in RA or whether the relationship is bi-directional\textsuperscript{31}. Apart from depression, a very common phenomenon in people with chronic pain is anxiety, which, similarly to depressive symptoms, influences the perception of pain and often leads to extreme focus on the symptoms of the disease\textsuperscript{33}. There is no clinical-based evidence that long-term treatment of pain with opioids is helpful in depressed and anxious patients who may be at greater risk of opioid side effects, including overdose, during the course of treatment\textsuperscript{27}.

**Addiction and threats during the COVID-19 pandemic**

The increase of opioid use has been observed worldwide, but it is particularly dramatic in the United States, where prescription sales quadrupled between 1999 and 2010\textsuperscript{34}, reaching 38\% of American adults taking opioids in 2015, and 17\% of these reported disorders related to opioid use\textsuperscript{21}, including increasing dependence and opioid abuse\textsuperscript{15}. The death rates caused by opioid poisoning also more than doubled between 2000 and 2013, with 81\% of these deaths being unintentional\textsuperscript{3}. Data on the use of opioids in chronic pain are similarly disturbing – it is believed that 21-29\% of patients have abused them\textsuperscript{14}. Compared to other drugs for chronic pain, opioids have a significantly increased risk of death from overdose\textsuperscript{21}. In Poland, in the years 2000-2015, there was a threefold increase in the use of opioid analgesics; there was an increase in the use of both weak and strong opioids, and almost 93\% of them were prescription for ambulatory use. These data, however, refer to the general use of opioids, there are no data on the use of opioids only in non-cancer pain, but it is worth emphasizing that the reported increase in opioid use is not only due to the increased incidence of neoplasms\textsuperscript{20}.

In recent years, numerous efforts have been made to reduce the use of opioids and combat addiction, but there are some data that the positive effects of these efforts have been wasted as a result of the COVID-19 pandemic. Some US states report an increase in opioid overdose of
up to 50% compared to the same period a year ago\textsuperscript{14}. Concern is also raised by the fact that COVID-19 affects people with chronic diseases more often as well as the group of chronic opioids users, and in addition, as a result of the pandemic, the social conditions that led to the opioid epidemic in the US, namely unemployment and isolation, may deteriorate\textsuperscript{14,35}.

**Other risks in people with RA**

From the point of view of public health, arthritis is a particularly important disease that should be considered separately in terms of opioid use, as the number of patients in the US is projected to increase from 1.5 million in 2007 to 67 million in 2030\textsuperscript{36}, but also complications of opioid use specific to patients with RA are clinically significant. Rheumatoid arthritis is associated with an increased risk of osteoporosis and fractures compared to the general adult population, and osteoporotic fractures are the third leading cause of death in RA patients and the second leading cause of disability\textsuperscript{37}. An additional factor predisposing to fractures is short-term (\(\leq 1\) month) use of strong opioids\textsuperscript{38}. The increased risk refers both vertebral and non-vertebral fractures, but the increase of risk is higher for vertebral fractures\textsuperscript{38,39}.

**Summary**

RA remains a difficult and challenging disease, especially when it comes to treating NSAID-resistant pain. While there are reliable studies supporting the safety and efficacy of the short-term use of opioids in the treatment of such pain, long-term treatment is still not supported by adequate studies, but is nevertheless often used in clinical practice. It is important to be aware of many dangers of chronic opioid use, also in combination with other medications that are frequently used by RA patients. Social factors and the individual characteristics of each patient should also be taken into account.

**References**

1. Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. *The Lancet* vol. 388 2023–2038 (2016).
2. Firestein, G. S. PATHOGENESIS OF RHEUMATOID ARTHRITIS: THE INTERSECTION OF GENETICS AND EPIGENETICS. Trans. Am. Clin. Climatol. Assoc. **129**, 171–182 (2018).
3. Zamora-Legoff, J. A. *et al.* Opioid use in patients with rheumatoid arthritis 2005–2014: a population-based comparative study. *Clin. Rheumatol.* (2016) doi:10.1007/s10067-016-3239-4.
4. Heiberg, T. & Kvien, T. K. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority. *Arthritis Care Res.* **47**, 391–397 (2002).
5. Heiberg, T., Finset, A. & Uhlig, T. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. *Ann Rheum Dis* **64**, 191–195 (2005).
6. Lee, Y. C. *et al.* Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. *Arthritis Rheumatol.* **66**, 2006–2014 (2014).
7. Koop, S. M. W., ten Klooster, P. M., Vonkeman, H. E., Steunebrink, L. M. M. & van de Laar, M. A. F. J. Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. *Arthritis Res. Ther.* **17**, (2015).
8. Lee, Y. C. et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: A longitudinal observational study. *Arthritis Res. Ther.* **13**, (2011).

9. Bas, D. B., Su, J., Wigerblad, G. & Svensson, C. I. Pain in rheumatoid arthritis: models and mechanisms. *Pain Manag.* **6**, 265–284 (2016).

10. Roche, P. A., Klestov, A. C. & Heim, H. M. Description of stable pain in rheumatoid arthritis: a 6 year study. *J. Rheumatol.* **30**, 1733–8 (2003).

11. Abbasi, M. et al. Strategies toward rheumatoid arthritis therapy; the old and the new. *J. Cell. Physiol.* **234**, 10018–10031 (2019).

12. Tomita, T., Ochi, T., Sugano, K., Uemura, S. & Makuch, R. W. Systematic review of NSAID-induced adverse reactions in patients with rheumatoid arthritis in Japan. *Modern Rheumatology* vol. 13 143–152 (2003).

13. Chen, Y. F. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation. *Health Technol. Assess. (Rocky)*. **12**, (2008).

14. The Lancet Rheumatology. Opioid use in rheumatic diseases: preventing another pandemic. *The Lancet Rheumatology* vol. 2 e447 (2020).

15. Hayes, C. J. et al. Health-Related Quality of Life among Chronic Opioid Users, Nonchronic Opioid Users, and Nonopioid Users with Chronic Noncancer Pain. *Health Serv. Res.* **53**, 3329–3349 (2018).

16. Rachinger-Adam, B., Conzen, P. & Azad, S. C. Pharmacology of peripheral opioid receptors. *Curr. Opin. Anaesthesiol.* **24**, 408–413 (2011).

17. Whittle, S. L., Richards, B. L., Husni, E. & Buchbinder, R. Opioid therapy for treating rheumatoid arthritis pain. *Cochrane Database Syst. Rev.* Art. No.: CD003113. (2011) doi:10.1002/14651858.cd003113.pub3.

18. Els, C. et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: An overview of Cochrane Reviews. *Cochrane Database of Systematic Reviews* vol. 2017 (2017).

19. What is a Serious Adverse Event? | FDA. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event.

20. Dzierżanowski, T. & Cialkowska-Rysz, A. Accessibility of opioid analgesics and barriers to optimal chronic pain treatment in Poland in 2000–2015. *Support. Care Cancer* **25**, 775–781 (2017).

21. Lee, Y. C., Kremer, J., Guan, H., Greenberg, J. & Solomon, D. H. Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors. *Arthritis Rheumatol.* **71**, 670–677 (2019).

22. Curtis, J. R. et al. Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. *Arthritis Rheumatol.* **69**, 1733–1740 (2017).

23. Whittle, S. L., Richards, B. L., Van Der Heijde, D. M. & Buchbinder, R. The efficacy and safety of opioids in inflammatory arthritis: A Cochrane systematic review. *Journal of Rheumatology* vol. 39 40–46 (2012).

24. Whittle, S. L., Richards, B. L. & Buchbinder, R. Opioid analgesics for rheumatoid arthritis pain. *JAMA - J. Am. Med. Assoc.* **309**, 485–486 (2013).
25. Hayes, C. J., Payakachat, N. & Li, C. Evaluation of opioid use among patients with back disorders and arthritis. *Qual. Life Res.* 27, 3021–3035 (2018).

26. Machado-Duque, M. E., Ramirez-Valencia, D. M., Murillo-Munoz, M. M. & Machado-Alba, J. E. Trends in Opioid Use in a Cohort of Patients with Rheumatoid Arthritis. *Pain Res. Manag.* 2020, (2020).

27. Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. *MMWR Recomm. Reports* 65, 1–49 (2016).

28. Machado-Alba, J. E., Gavarria-Mendoza, A., Vargas-Mosquera, C. A., Gil-Restrepo, A. F. & Romero-Zapata, L. C. Opioid Prescribing Patterns and Costs in a Large Group of Patients in Colombia. *J. Pain Palliat. Care Pharmacother.* 31, 57–65 (2017).

29. Palsson, O. *et al.* OP0088 INITIATING TNF INHIBITORS IN INFLAMMATORY ARTHRITIS DOES NOT DECREASE THE AVERAGE OPIOID ANALGESIC CONSUMPTION. *Ann. Rheum. Dis.* 79, 58–59 (2020).

30. Rapti, E. *et al.* Patients with chronic pain: Evaluating depression and their quality of life in a single center study in Greece. *BMC Psychol.* 7, (2019).

31. Englbrecht, M. *et al.* New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study. *PLoS One* 14, (2019).

32. Lisitsyna, T. A. *et al.* Chronic pain and depression in patients with rheumatoid arthritis: Results of five-year follow-up. *Ter. Arkh.* 91, 8–18 (2019).

33. Kostov, S. & Schug, S. Depression and chronic pain. *Saudi Journal of Anaesthesia* vol. 12 377–378 (2018).

34. Nelson, L. S. & Perrone, J. Curbing the opioid epidemic in the United States: The risk evaluation and mitigation strategy (REMS). *JAMA - Journal of the American Medical Association* vol. 308 457–458 (2012).

35. Becker, W. C. & Fiellin, D. A. When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis. *Annals of internal medicine* vol. 173 59–60 (2020).

36. Arthritis-Related Statistics | Data and Statistics | Arthritis | CDC. https://www.cdc.gov/arthritis/data_statistics/arthritis-related-stats.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Farthritis%2Fdata_statistics%2Farthritis_related_stats.htm.

37. Michaud, K. & Wolfe, F. Comorbidities in rheumatoid arthritis. *Best Practice and Research: Clinical Rheumatology* vol. 21 885–906 (2007).

38. Ozen, G., Pedro, S., Wolfe, F. & Michaud, K. Medications associated with fracture risk in patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 78, 1041–1047 (2019).

39. Acucio, F. A., Moura, C. S., Bernatsky, S., Bessette, L. & Rahme, E. Opioid Use and Risk of Nonvertebral Fractures in Adults with Rheumatoid Arthritis: A Nested Case-Control Study Using Administrative Databases. *Arthritis Rheumatol.* 68, 83–91 (2016).